MMP2 expression is a prognostic marker for primary melanoma patients

Cellular Oncology

Volumn 35, Issue 3, 2012, Pages 207-216

  Rotte, Anand ^a   Martinka, Magdalena ^b   Li, Gang ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c JACK BELL RESEARCH CENTRE   (Canada)

Author keywords

Melanoma; MMP2; P Akt; Patient survival

Indexed keywords

GELATINASE A; PROTEIN KINASE B;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DYSPLASTIC NEVUS; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR BIOPSY; TUMOR VOLUME; ULCER;

AGED; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 2; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR MARKERS, BIOLOGICAL;

EID: 84869987776     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-012-0080-x     Document Type: Article

References (29)

1. T.L. Diepgen, V. Mahler, The epidemiology of skin cancer. Br. J. Dermatol. 146(Suppl 61), 1-6 (2002)
2. A.C. Geller, S.M. Swetter, K. Brooks, M.F. Demierre, A.L. Yaroch, Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J. Am. Acad. Dermatol. 57(4), 555-572 (2007). quiz 573-556 (Pubitemid 47384936)
3. A.J. Miller, M.C. Mihm Jr., Melanoma. New Engl. J. Med. 355(1), 51-65 (2006)
4. H. Tsao, A.J. Sober, Melanoma treatment update. Dermatol. Clin. 23(2), 323-333 (2005)
5. M.B. Lens, T.G. Eisen, Systemic chemotherapy in the treatment of malignant melanoma. Expert. Opin. Pharmacother. 4(12), 2205-2211 (2003) (Pubitemid 37541234)
6. C.M. Balch, S.J. Soong, J.E. Gershenwald, J.F. Thompson, D.S. Reintgen, N. Cascinelli et al., Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19(16), 3622-3634 (2001) (Pubitemid 32786275)
7. A.N. Houghton, D. Polsky, Focus on melanoma. Canc. Cell. 2(4), 275-278 (2002) (Pubitemid 41043961)
8. R.M. Turner, K.J. Bell, R.L. Morton, A. Hayen, A.B. Francken, K. Howard et al., Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J. Clin. Oncol. 29(35), 4641-4646 (2011)
9. K.Y. Bilimoria, M.V. Raval, D.J. Bentrem, J.D. Wayne, C.M. Balch, C.Y. Ko, National assessment of melanoma care using formally developed quality indicators. J. Clin. Oncol. 27(32), 5445-5451 (2009)
10. A.C. Geller, S.M. Swetter, S. Oliveria, S. Dusza, A.C. Halpern, Reducing mortality in individuals at high risk for advanced melanoma through education and screening. J. Am. Acad. Dermatol. 65 (5), S87-94 (2011)
11. C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, D.R. Byrd et al., Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27(36), 6199-6206 (2009)
12. J.F. Thompson, S.J. Soong, C.M. Balch, J.E. Gershenwald, S. Ding, D.G. Coit et al., Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J. Clin. Oncol. 29(16), 2199-2205 (2011)
13. M. Bjorklund, E. Koivunen, Gelatinase-mediated migration and invasion of cancer cells. Biochim. Biophys. Acta. 1755(1), 37-69 (2005) (Pubitemid 40720240)
14. E.I. Deryugina, J.P. Quigley, Matrix metalloproteinases and tumor metastasis. Canc. Metastasis Rev. 25(1), 9-34 (2006) (Pubitemid 43723979)
15. C.E. Brinckerhoff, J.L. Rutter, U. Benbow, Interstitial collagenases as markers of tumor progression. Clin. Canc. Res. 6(12), 4823-4830 (2000) (Pubitemid 32110426)
16. U.B. Hofmann, J.R. Westphal, G.N. Van Muijen, D.J. Ruiter, Matrix metalloproteinases in human melanoma. J. Invest. Dermatol. 115(3), 337-344 (2000)
17. U.B. Hofmann, J.R. Westphal, A.J. Zendman, J.C. Becker, D.J. Ruiter, G.N. van Muijen, Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J. Pathol. 191(3), 245-256 (2000) (Pubitemid 30441247)
18. T. Turpeenniemi-Hujanen, Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 87(3-4), 287-297 (2005) (Pubitemid 40387607)
19. A.H. Vaisanen, M. Kallioinen, T. Turpeenniemi-Hujanen, Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum. Pathol. 39(3), 377-385 (2008)
20. S. Shukla, G.T. Maclennan, D.J. Hartman, P. Fu, M.I. Resnick, S. Gupta, Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int. J. Canc. 121(7), 1424-1432 (2007) (Pubitemid 47328700)
21. V. Vasko, M. Saji, E. Hardy, M. Kruhlak, A. Larin, V. Savchenko et al., Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J. Med. Genet. 41 (3), 161-170 (2004) (Pubitemid 38333792)
22. D.L. Dai, M. Martinka, G. Li, Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J. Clin. Oncol. 23(7), 1473-1482 (2005)
23. K.M. Sze, K.L. Wong, G.K. Chu, J.M. Lee, T.O. Yau, I. Oi-Lin Ng, Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology 53(5), 1558-1569 (2011)
24. H. Lin, R.P. Wong, M. Martinka, G. Li, Loss of SNF5 expression correlates with poor patient survival in melanoma. Clin. Canc. Res. 15(20), 6404-6411 (2009)
25. W. Remmele, H.E. Stegner, Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8(3), 138-140 (1987)
26. A. Vaisanen, P. Kuvaja, M. Kallioinen, T. Turpeenniemi-Hujanen, A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Hum. Pathol. 42(8), 1103-1111 (2011)
27. F. Su, W.D. Bradley, Q. Wang, H. Yang, L. Xu, B. Higgins et al., Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res. 72(4), 969-978 (2012)
28. J.A. Sparano, P. Bernardo, P. Stephenson, W.J. Gradishar, J.N. Ingle, S. Zucker et al., Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J. Clin. Oncol. 22(23), 4683-4690 (2004)
29. R.L. Camp, V. Neumeister, D.L. Rimm, A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J. Clin. Oncol. 26(34), 5630-5637 (2008)